The latest peer-reviewed articles on TB and HIV; respiratory diseases such as asthma and COPD; and the hazards of tobacco and air pollution. Recent coverage has expended to include COVID-19 and the interplay between TB-COVID-19 and other co-morbidities.
In 2021, we will launch the first of a new series – The IJTLD Clinical Standards for Lung Health - written by a global authorship of experts for each area of lung health.
Because many authors do not have funding for Open Access, the IJTLD is a hybrid journal (i.e., a subscription-based journal that offers an OA option for authors with funds available).A subscription provides immediate access to Original Articles, State of the Art Reviews, Letters and Correspondence on clinical and biological aspects of lung disease and lung health,
Union members can get support with access – please contact Union Membership.
Advertising or sponsoring content is an effective means of reaching clinicians, researchers, health workers, decision makers and students.
Sponsors can support the creation of a Collection or a Supplement on a relevant topic of interest, either in print or a digital collection of articles, for elevated visibility of your products and services.
Other opportunities include being involved in the creation of informative Posters, Infographics, or scientific Animations to clarify relevant biological processes.
The IJTLD welcomes submissions on COVID-19 and we fast-track articles on topical issues, including the potential impact on TB services and articles that improve our understanding of the role that other risk factors – including diabetes, obesity, smoking, air quality, asthma and COPD – have on the impact of COVID-19.
IJTLD Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and publishing them in full on our website, prior to their publication in the Journal. Read fast-track articles:
In this State of the Art, the authors reviewed the literature on thromboembolic adverse events reported after vaccination for COVID-19, and review the benefits and risks of the vaccines approved for use. The preprint is free to read.
On 18th July 2021, we celebrate the 100th anniversary of the first use of the BCG vaccine for TB. An Editorial in IJTLD discusses BCG’s efficacy, heterologous protection and controversial link with COVID-19. The preprint is free to read.
An Editorial for IJTLD highlights the importance of TB preventive treatment (TPT) and the launch by WHO, governments, civil society and other partners of a ‘Call to Action’ for broader access to TPT for those in need. The article is free to read.